Zhai Xiangjun, Liu Jiyong, Hu Zhibin, Wang Shui, Qing Jianwei, Wang Xuechen, Jin Guangfu, Gao Jun, Wang Xinru, Shen Hongbing
Laboratory of Reproductive Medicine, Nanjing Medical University School of Public Health, China.
Oncol Rep. 2006 Jan;15(1):247-52.
Adenosine diphosphate ribosyl transferase (ADPRT) and X-ray repair cross-complementing 1 (XRCC1) are two major base excision repair (BER) proteins and act cooperatively in the BER processes. Polymorphisms of ADPRT Val762Ala and XRCC1 Arg399Gln may alter their protein functions and BER activity, and were therefore hypothesized to be associated with breast cancer susceptibility. We examined the contributions of these two polymorphisms to breast cancer susceptibility in a case-control study of 302 breast cancer cases, 221 patients with benign breast disease (BBD) and 639 cancer-free controls in a Chinese population. We found that the variant genotypes of both ADPRT Val762Ala and XRCC1 Arg399Gln were not significantly associated with the risk of breast cancer (adjusted OR 0.87, 95% CI 0.64 to 1.19 for ADPRT Val/Ala + Ala/Ala; adjusted OR 0.82, 95% CI 0.61 to 1.11 for XRCC1 Arg/Gln + Gln/Gln; and adjusted OR 0.70, 95% CI 0.45 to 1.10 for these two combined variant genotypes. Similarly, we did not find any significant associations of these two genotypes with BBD risk. These findings suggest that the ADPRT Val762Ala and XRCC1 Arg399Gln polymorphisms may not play a role in the etiology of breast cancer.
二磷酸腺苷核糖基转移酶(ADPRT)和X射线修复交叉互补蛋白1(XRCC1)是两种主要的碱基切除修复(BER)蛋白,在BER过程中协同发挥作用。ADPRT Val762Ala和XRCC1 Arg399Gln的多态性可能会改变其蛋白质功能和BER活性,因此推测它们与乳腺癌易感性有关。我们在中国人群中进行了一项病例对照研究,纳入302例乳腺癌患者、221例乳腺良性疾病(BBD)患者和639例无癌对照,以检验这两种多态性对乳腺癌易感性的影响。我们发现,ADPRT Val762Ala和XRCC1 Arg399Gln的变异基因型均与乳腺癌风险无显著关联(ADPRT Val/Ala + Ala/Ala的校正OR为0.87,95%CI为0.64至1.19;XRCC1 Arg/Gln + Gln/Gln的校正OR为0.82,95%CI为0.61至1.11;这两种联合变异基因型的校正OR为0.70,95%CI为0.45至1.10)。同样,我们未发现这两种基因型与BBD风险有任何显著关联。这些发现表明,ADPRT Val762Ala和XRCC1 Arg399Gln多态性可能在乳腺癌病因学中不起作用。